Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Randomized, Double-Blind Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) in Children at High Risk for the Development of Serious RSV Disease

NCT00233064 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT00233064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00233064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Randomized, Double-Blind Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) in Children at High Risk for the Development of Serious RSV Disease
Lead sponsor
MedImmune LLC
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2005
Completion date
November 30, 2007
Enrollment
417 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lung disease